inclusion criteria: * male or female 18 years of age or older at the time of enrollment. * patients hospitalized with a positive rt-pcr for sars-cov-2 within the last 14 days, with illness duration within the last 14 days, and evidence of moderate to severe covid-19 infection as defined by nih covid-19 severity categorization (8): * moderate illness: individuals who show evidence of lower respiratory disease during clinical assessment or imaging and who have saturation of oxygen spo2≥ 94% on room air at sea level. * severe illness: individuals who have spo2 \<94% on room air at sea level, a ratio of arterial partial pressure of oxygen to fraction of inspired oxygen (pao2/fio2) \<300 mm hg, respiratory frequency \>30 breaths/min, or lung infiltrates \>50%. * patient and/or legally authorized representative is willing and able to provide written informed consent and comply with all protocol requirements. * patients with hematologic malignancies or solid tumors are eligible. * patients with autoimmune disorders are eligible. * patients with immunodeficiency and organ or stem cell transplant recipients are eligible. * patients with acute or chronic renal injury/failure are eligible. * patients with neutropenia/lymphopenia are eligible. * patients with elevated liver function tests are eligible. * women who are not taking contraception are eligible. * patients who are currently or have recently received steroids and/or remdesivir are eligible. * patient agrees to not participate in another clinical trial for the treatment of covid-19 through end of study period.

inclusion criteria: * male or female 18 years of age or older at the time of enrollment. * patients hospitalized with a positive rt-pcr for sars-cov-2 within the last 14 days, with illness duration within the last 14 days, and evidence of moderate to severe covid-19 infection as defined by nih covid-19 severity categorization (8): * moderate illness: individuals who show evidence of lower respiratory disease during clinical assessment or imaging and who have saturation of oxygen spo2≥ 94% on room air at sea level. * severe illness: individuals who have spo2 \<94% on room air at sea level, a ratio of arterial partial pressure of oxygen to fraction of inspired oxygen (pao2/fio2) \<300 mm hg, respiratory frequency \>30 breaths/min, or lung infiltrates \>50%. * patient and/or legally authorized representative is willing and able to provide written informed consent and comply with all protocol requirements. * patients with hematologic malignancies or solid tumors are eligible. * patients with autoimmune disorders are eligible. * patients with immunodeficiency and organ or stem cell transplant recipients are eligible. * patients with acute or chronic renal injury/failure are eligible. * patients with neutropenia/lymphopenia are eligible. * patients with elevated liver function tests are eligible. * women who are not taking contraception are eligible. * patients who are currently or have recently received steroids and/or remdesivir are eligible. * patient agrees to not participate in another clinical trial for the treatment of covid-19 through end of study period.

inclusion criteria: male or female 18 years of age or older at the time of enrollment. patients hospitalized with a positive rt-pcr for sars-cov-2 within the last 14 days, with illness duration within the last 14 days, and evidence of moderate to severe covid-19 infection as defined by nih covid-19 severity categorization (8): moderate illness: individuals who show evidence of lower respiratory disease during clinical assessment or imaging and who have saturation of oxygen spo2≥ 94% on room air at sea level. severe illness: individuals who have spo2 <94% on room air at sea level, a ratio of arterial partial pressure of oxygen to fraction of inspired oxygen (pao2/fio2) <300 mm hg, respiratory frequency >30 breaths/min, or lung infiltrates >50%. patient and/or legally authorized representative is willing and able to provide written informed consent and comply with all protocol requirements. patients with hematologic malignancies or solid tumors are eligible. patients with autoimmune disorders are eligible. patients with immunodeficiency and organ or stem cell transplant recipients are eligible. patients with acute or chronic renal injury/failure are eligible. patients with neutropenia/lymphopenia are eligible. patients with elevated liver function tests are eligible. women who are not taking contraception are eligible. patients who are currently or have recently received steroids and/or remdesivir are eligible. patient agrees to not participate in another clinical trial for the treatment of covid-19 through end of study period.

inclusion criteria: male or female 18 years of age or older at the time of enrollment. patients hospitalized with a positive rt-pcr for sars-cov-2 within the last 14 days, with illness duration within the last 14 days, and evidence of moderate to severe covid-19 infection as defined by nih covid-19 severity categorization (8): moderate illness: individuals who show evidence of lower respiratory disease during clinical assessment or imaging and who have saturation of oxygen spo2≥ 94% on room air at sea level. severe illness: individuals who have spo2 <94% on room air at sea level, a ratio of arterial partial pressure of oxygen to fraction of inspired oxygen (pao2/fio2) <300 mm hg, respiratory frequency >30 breaths/min, or lung infiltrates >50%. patient and/or legally authorized representative is willing and able to provide written informed consent and comply with all protocol requirements. patients with hematologic malignancies or solid tumors are eligible. patients with autoimmune disorders are eligible. patients with immunodeficiency and organ or stem cell transplant recipients are eligible. patients with acute or chronic renal injury/failure are eligible. patients with neutropenia/lymphopenia are eligible. patients with elevated liver function tests are eligible. women who are not taking contraception are eligible. patients who are currently or have recently received steroids and/or remdesivir are eligible. patient agrees to not participate in another clinical trial for the treatment of covid-19 through end of study period.

inclusion criteria: - patients hospitalized with a positive rt-pcr for sars-cov-2 within the last 14 days, with illness duration within the last 14 days, and evidence of moderate to severe covid-19 infection as defined by nih covid-19 severity categorization (8): - moderate illness: individuals who show evidence of lower respiratory disease during clinical assessment or imaging and who have saturation of oxygen spo2≥ 94% on room air at sea level. - severe illness: individuals who have spo2 <94% on room air at sea level, a ratio of arterial partial pressure of oxygen to fraction of inspired oxygen (pao2/fio2) <300 mm hg, respiratory frequency >30 breaths/min, or lung infiltrates >50%. - patient and/or legally authorized representative is willing and able to provide written informed consent and comply with all protocol requirements. - patients with hematologic malignancies or solid tumors are eligible. - patients with autoimmune disorders are eligible. - patients with immunodeficiency and organ or stem cell transplant recipients are eligible. - patients with acute or chronic renal injury/failure are eligible. - patients with neutropenia/lymphopenia are eligible. - patients with elevated liver function tests are eligible. - women who are not taking contraception are eligible. - patients who are currently or have recently received steroids and/or remdesivir are eligible. - patient agrees to not participate in another clinical trial for the treatment of covid-19 through end of study period.

inclusion criteria: - patients hospitalized with a positive rt-pcr for sars-cov-2 within the last 14 days, with illness duration within the last 14 days, and evidence of moderate to severe covid-19 infection as defined by nih covid-19 severity categorization (8): - moderate illness: individuals who show evidence of lower respiratory disease during clinical assessment or imaging and who have saturation of oxygen spo2≥ 94% on room air at sea level. - severe illness: individuals who have spo2 <94% on room air at sea level, a ratio of arterial partial pressure of oxygen to fraction of inspired oxygen (pao2/fio2) <300 mm hg, respiratory frequency >30 breaths/min, or lung infiltrates >50%. - patient and/or legally authorized representative is willing and able to provide written informed consent and comply with all protocol requirements. - patients with hematologic malignancies or solid tumors are eligible. - patients with autoimmune disorders are eligible. - patients with immunodeficiency and organ or stem cell transplant recipients are eligible. - patients with acute or chronic renal injury/failure are eligible. - patients with neutropenia/lymphopenia are eligible. - patients with elevated liver function tests are eligible. - women who are not taking contraception are eligible. - patients who are currently or have recently received steroids and/or remdesivir are eligible. - patient agrees to not participate in another clinical trial for the treatment of covid-19 through end of study period.